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Background: Patients with treated Human Immunodeficiency Virus-1 (HIV) infection are at increased risk of
cardiovascular events. Traditionally much of this risk has been attributed to metabolic and anthropometric
abnormalities associated with HIV, which are similar to the metabolic syndrome (MS), an established risk factor for
cardiovascular mortality. It remains unclear whether treated HIV infection is itself associated with increased risk, via
increase vascular stiffness.
Methods: 226 subjects (90 with HIV) were divided into 4 groups based on HIV and MS status: 1) HIV-ve/MS-ve,
2) HIV-ve/MS + ve, 3) HIV + ve/MS-ve and 4)HIV + ve/MS + ve. CMR was used to determine aortic pulse wave velocity
(PWV) and regional aortic distensibility (AD).
Results: PWV was 11% higher and regional AD up to 14% lower in the HIV + ve/MS-ve group when compared to
HIV-ve/MS-ve (p < 0.01 all analyses). PWV and AD in the HIV + ve/MS-ve group was similar to that observed in the
HIV-ve/MS + ve group (p > 0.99 all analyses). The HIV + ve/MS + ve group had 32% higher PWV and 30-34% lower
AD than the HIV-ve/MS-ve group (all p < 0.001), and 19% higher PWV and up to 31% lower AD than HIV + ve/MS-ve
subjects (all p < 0.05). On multivariable regression, age, systolic blood pressure and treated HIV infection were all
independent predictors of both PWV and regional AD.
Conclusion: Across multiple measures, treated HIV infection is associated with increased aortic stiffness and is also
an independent predictor of both PWV and regional AD. The magnitude of the effect of treated HIV and MS are
similar, with additive detrimental effects on central vascular elasticity.
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Effective antiretroviral therapy has markedly improved
life expectancy in the HIV-infected population. However,
despite immunological modulation, aging with HIV is
accompanied by an increased prevalence of metabolic
abnormalities, atherosclerotic cardiovascular disease and
higher all-cause mortality [1-4]. The pathogenesis of this
accelerated atherosclerosis in HIV has not been fully
elucidated. Even after adjusting for traditional risk factors,
which tend to have a higher prevalence in the treated HIV
population, elevated rates of coronary disease remain [2].* Correspondence: oliver.rider@gmail.com
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unless otherwise stated.Recent studies have suggested that viral factors, in
addition to traditional vascular risk factors, have inde-
pendent negative effects, possibly by promoting athero-
genic lipid abnormalities [5], monocyte attraction and
migration into the vascular intima [6] and a chronic in-
flammatory state [7,8], all of which produce an environ-
ment for accelerated atherogenesis.
In addition, treated HIV is associated with an increase
in the prevalence of the cluster of metabolic risk factors
that make up the metabolic syndrome [9]. Metabolic
complications appear to result from treatments for HIV
and, to some degree, from the effect of viral infection itself
[10-13]. Whether viral factors amplify the atherogenic ef-
fect of traditional metabolic risk factors in HIV-infected
individuals remains unclear.
Both aortic pulse wave velocity (PWV) and regional
aortic distensibility (AD) are sensitive markers of aorticd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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measure of arterial stiffness that has not only been
shown to be predictive of both cardiovascular events
and mortality in multiple population studies, [14,15] but
is also a well-validated surrogate marker of atheroscler-
osis, corresponding closely to the degree of atheroscler-
osis as assessed by both computed tomography and
post-mortem studies [16]. The aim of this study was to
use PWV and AD to investigate 1) if HIV is independ-
ently associated with increased arterial stiffness, 2) the
magnitude of the detrimental effect of HIV on aortic
elastic function when compared to the metabolic syn-
drome and 3) whether or not the metabolic syndrome
and HIV are additive in their detrimental effects.Methods
Study cohort
90 patients with documented HIV infection (13 naive to
antiretroviral therapy) and 136 subjects with no history
of HIV infection were recruited to this study. Eligibility
criteria were age over 18 years, no history or symptoms
of cardiovascular disease and no contraindications to
cardiovascular magnetic resonance (CMR). All patients
with HIV were treated in accordance with national guide-
lines. Patients with HIV and non-infected subjects were
subdivided into those with and without the metabolic syn-
drome according to the National Cholesterol Education
Program-Adult Treatment Panel III (NCEP-ATP III)
guidelines [17]. Subjects were diagnosed with the MS
when at least 3 of 5 risk determinants increased waist
circumference, increased systolic blood pressure (SBP)
or diastolic blood pressure (DBP), elevated serum triglyc-
erides, low high-density lipoprotein cholesterol (HDL-C),
and impaired fasting glucose (IFG) were present. Subjects
were then separated into 4 groups: 1) healthy controls
without the MS (HIV-ve/MS-ve), 2) controls with the MS
(HIV-ve/MS + ve), 3) patients with HIV without the
MS (HIV + ve/MS-ve) and 4) patients with HIV and the
MS (HIV + ve/MS + ve). This study was approved by
the local ethics committee (ref. 10/H0604/95) and all
subjects gave informed written consent prior to participa-
tion. Ethics was approved by the Oxford Research Ethics
Committee.Anthropometric data
Morning assessments took place after a minimum
10 hour fast. Height and weight were measured using a
digital station (Seca, UK) and used to calculate body
mass index (BMI, mass (kg)/height (m)2). Waist circum-
ferences were measured in the standing position at the
level of the umbilicus with the average of three measure-
ments taken. Data on duration of HIV infection, nadir
CD4 count and Highly Active Antiretroviral Therapy(HAART) were obtained from the treating physicians
with the consent of the patients.
A fasting blood sample was obtained for measurement
of plasma glucose, free fatty acids, hs-CRP, cholesterol
and hs-CRP and were analysed by a commercial hospital
laboratory. Insulin was measured using ELISA (Mercodia
AB, Uppsala, Sweden). To calculate the homeostasis
model assessment for insulin resistance (HOMA-IR) the
following formula was used: fasting insulin (pmol/l) ×
fasting glucose (mM/l)/135 and used as a measure of
insulin resistance [18].
CMR protocol for aortic distensibility
All vascular imaging was performed at 1.5-Tesla (Avanto,
Siemens Medical Solutions, Erlangen, Germany). Based on
sagittal-oblique (candy cane) pilot images aligned with the
aortic arch, thoracic aortic cine images were acquired in
transverse planes at 3 levels as previously described: [19]
the crossing of the pulmonary arch through 1) the ascend-
ing thoracic aorta (Ao), 2) proximal descending thoracic
aorta (PDA) and 3) 12 cm below the PDA level piloted
perpendicular to the orientation of the aorta (distal de-
scending aorta, DDA). A brachial artery blood pressure
was recorded during image acquisition to provide pulse
pressure [20].
CMR protocol for aortic pulse wave velocity
To measure aortic PWV, images were acquired using a
free-breathing, retrospectively ECG-gated, spoiled gradi-
ent echo sequence. Velocity-encoding gradient for phase
contrast was applied to measure through-plane flow in
the ascending aorta at the same three levels used for
aortic distensibility. Oblique sagittal images were used to
calculate the distance between the two imaging levels as
previously described (Figure 1) [21].
CMR protocols for visceral fat mass
To measure visceral fat mass, a single breath-hold,
single-slice, water-suppressed T1-weighted turbo spin
echo sequence centred on L5 was acquired as previously
described [22].
Image analysis
Image analysis was performed using Siemens analytical
software (Argus ©, Siemens Medical Solutions, Erlangen,
Germany). To analyse aortic PWV, flow images were
manually contoured [23] and aortic PWV was determined
as Δx/Δt (m/s), where Δx is the aortic distance between
two imaging levels and Δt is time delay between the arrival
of the foot of the pulse wave between these imaging levels
(Figure 1) [24]. The arrival of the foot of the pulse wave
was taken as the intersection of the tangent (determined
by a least squares method of the four flow points around
the half maximal point of flow) of the upslope of the flow
A B
Figure 1 Calculating pulse wave velocity. A. Distance Δx was taken as the total distance between A (ascending aorta) and C (abdominal
aorta). This was calculated using the sum of the distances between the centre points of lines drawn at 45°, 90° and 135° to the scan level.
B. Aortic flow/time curves used to calculate the arrival times of aortic pulse waveform. Δt represents the time (m/s) between the intercepts (b-a)
of the tangents to the curve at the half maximal point of flow in the ascending aorta (a) and the abdominal aorta (b).
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To assess visceral fat mass, transverse slices were manually
countered as previously described [25].
Statistical analysis
All statistical analyses were performed using SPSS
statistical software (version 19.0; SPSS Inc., Chicago,
Ill, USA). Normality of distribution was assessed using
the Kolmogorov-Smirnov test. Normally distributed
data are presented as mean ± standard deviation, non-
normally distributed data as median (interquartile
range). Comparisons between normally distributed data
in the 4 groups identified above were performed with
one-way analysis of variance with post-hoc Bonferroni
correction. Bivariate correlations for all subjects were
calculated using Pearson correlation coefficients. Sig-
nificance was assumed at a probability value of p < 0.05.
Variables with p < 0.05 and the strongest relationship
with aortic pulse wave velocity and AD were then in-
cluded as independent variables in forced entry stepwise
multiple regression analysis with aortic PWV and AD as
the dependent variables.
Results
Baseline characteristics of the study populations
Anthropometric data for the study group when divided
into the four groups is shown in Table 1. The immuno-
logical, virological and HAART status of patients with
HIV are presented in Table 2.
The effect of HIV on aortic elastic function
To isolate the effect of HIV alone on aortic PWV and AD,
patients with HIV but without the metabolic syndrome
(HIV + ve/MS-ve, n = 73) were compared to non-infected
subjects without the metabolic syndrome (HIV-ve/MS-ve,n = 92). The two groups were well matched for age, blood
pressure, BMI, visceral fat, waist circumference, triglycer-
ides, cholesterol, glucose, HOMA-IR and smoking status
(Table 1). In agreement with the published literature, HIV
infection was associated with reduced HDL cholesterol,
a higher prevalence of smoking and an elevated high
sensitivity C- reactive protein level (hs-CRP, Table 1).
PWV was 11% higher in the HIV + ve/MS-ve group
when compared to the HIV-ve/MS-ve group (6.2 ± 1.9
vs 5.6 ± 1.9 m/s, p = 0.008, Figure 2) and aortic distensi-
bility reduced (PDA by 12%, AA by 14%, both p < 0.01,
Figure 3). Put together this suggests that HIV alone
causes increased aortic stiffness. Of note, there was no
difference between regional AD and PWV when compar-
ing HAART naïve (n = 13) to HAART treated (n = 77)
subjects (p >0.2 for all analyses).
Comparing the effects of HIV and the metabolic
syndrome on aortic elastic function
In order to compare the effect of HIV and the Metabolic
syndrome on PWV and AD, subjects with the metabolic
syndrome but without a history of HIV infection (HIV-ve/
MS + ve, n = 44) were compared to patients with HIV in-
fection without the metabolic syndrome (HIV + ve/MS-ve,
n = 73). As expected, the group with metabolic syndrome
had higher blood pressures, BMI, visceral fat and waist
circumference when compared to the group without
metabolic syndrome (Table 1). Interestingly, despite this,
both the HIV-ve/MS + ve and the HIV + ve/MS-ve groups
had similar PWV (6.7 ± 1.9 vs 6.2 ± 1.9 m/s p = 0.94),
which were 16-20% higher than the HIV-ve/MS-ve group
(p < 0.05 for both analyses). A similar pattern was seen
comparing distensibility in the HIV-ve/MS + ve and the
HIV + ve/MS-ve with aortic distensibility measures at all
three levels of the aorta being similar across the two groups







HIV + ve/MS + ve
(n = 17)
P value from analysis
of variance
Age (years) 45 ± 10 49 ± 11 44 ± 10 48 ± 8 0.12
BMI (kg/m2) 25 ± 4 33 ± 7* 25 ± 4Φ 30 ± 6*ψ <0.001
Visceral Fat (cm2) 71 ± 39 160 ± 71* 86 ± 49Φ 120 ± 66* <0.001
0.9 ± 0.5 1.7 ± 0.8* 1.3 ± 1.0 2.4 ± 1.7*ψ <0.001
Cholesterol (mmol/L) 4.8 ± 0.9 5.1 ± 1.2 4.5 ± 1.4 4.6 ± 1.4 0.110
HDL-C (mmol/L) 1.6 ± 0.4 1.1 ± 0.3* 1.2 ± 0.4* 1.0 ± 0.4* <0.001
Glucose (mmol/L) 4.8 ± 0.5 5.4 ± 0.8* 5.0 ± 0.8 6.0 ± 1.3*Φψ <0.001
HOMA-IR 1.1 ± 1.0 3.5 ± 2.7* 1.4 ± 1.3Φ 4.6 ± 6.1*ψ <0.001
hs-CRP (mg/L) 0.7 ± 1.6 3.1 ± 4.0* 2.2 ± 2.7* 4.6 ± 4.5*ψ <0.001
SBP (mmHg) 117 ± 12 130 ± 14* 118 ± 16Φ 138 ± 16*ψ <0.001
DBP (mmHg) 73 ± 9 80 ± 8* 75 ± 9Φ 85 ± 8*ψ <0.001
Waist circumference (cm) 88 ± 14 110 ± 17* 89 ± 11Φ 106 ± 16*ψ <0.001
Smoking (%) 32 32 37 41 0.799
PWV (m/s) 5.6 ± 1.0 6.7 ± 1.7* 6.2 ± 1.9* 7.4 ± 2.4*ψ <0.001
*p < 0.05 versus HIV-ve/MS-ve.
Φp < 0.05 versus HIV-ve/MS + ve.
ψp < 0.05 versus HIV + ve/MS-ve.
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have a similar magnitude of effect on aortic elastic function.
Investigating an additive effect of treated HIV and the
metabolic syndrome
To investigate whether HIV and the metabolic syndrome
are additive in their negative effects on PWV, patients
with HIV infection without the metabolic syndrome
(HIV + ve/MS-ve, n = 73) were compared to subjects
with both HIV infection and the metabolic syndrome
(HIV + ve/MS + ve, n = 17). As would be expected the
HIV + ve/MS + ve group had increased BMI, SBP, DBP,
waist circumference, HOMA-IR, glucose and hs-CRP
when compared to the HIV+/MS-ve group (Table 1).
Again, as expected, both the HIV + ve/MS-ve and the
HIV + ve/MS + ve groups had higher PWV than theTable 2 HIV specific data for the HIV + ve/MS-ve and HIV + ve
range)
HIV + ve/MS-ve
On HAART (n = 61) No
Duration of HIV infection (years) 6 (7) 2 (
Time on HAART (years) 3 (5) -
Nadir CD4 cell count (106/L) 190 (170) 560
Current CD4 cell count (106/L) 515 (218) 640
HIV viral load (copies/mL) 10 (10) 896
Protease inhibitors (%) 21 -
NRTI (%) 81 -
NNRTI (%) 61 -HIV-ve/MS-ve group (PWV by 15% and 38% respectively
p < 0.05 for both analyses) In agreement with this, both
the HIV + ve/MS-ve and the HIV + ve/MS + ve groups
had lower aortic distensibility than the HIV-ve/MS-ve
group (Ao by 16% and 44%, PDA by 20% and 45%, DDA
by 18% and 38%, respectively all p < 0.05). Importantly,
PWV in the HIV + ve/MS + ve group was 19% higher and
aortic distensibility 31%, lower (= 0.011, Figure 3) than that
recorded in the HIV + ve/MS-ve group (7.4 ± 2.4 vs 6.2 ±
1.9 m/s, p < 0.05). Put together, this suggests an additive
detrimental effect of HIV and the metabolic syndrome on
aortic elastic function.
Determinants of aortic PWV in study population
In order to investigate the associations between PWV
and other study parameters of the metabolic syndrome/MS + ve groups, data presented as median (Interquartile
HIV + ve/MS + ve
HAAR (n = 12) On HAART (n = 16) No HAART (n = 1)
4) 8 (9) 6
6 (7) -
(425) 170 (190) 300
(400) 550 (255) 300




Figure 2 The effect of HIV and the metabolic syndrome on
aortic pulse wave velocity.
Figure 3 The effect of HIV and the metabolic syndrome on
aortic distensibility. For Clarity Only Differences in Distensibility
Reaching a Statistical Significance of p < 0.05 are Highlighted.
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analysis. Associations between anthropometric, metabolic
and HIV-related characteristics and aortic PWV are pre-
sented in Table 3. In agreement with the published litera-
ture, aortic PWV was positively correlated with age, BMI,
systolic blood pressure, diastolic blood pressure, waist cir-
cumference, visceral fat mass, fasting serum glucose and
hs-CRP levels. Interestingly, HIV infection per se, current
CD4 count and smoking status were also positively
correlated with PWV. Importantly, there was no asso-
ciation between duration of HAART, antiretroviral
class, viral load or nadir CD4 count and aortic PWV.
To investigate if there were any independent predictors
of pulse wave velocity, multivariable regression was
used as described above. The strongest stepwise multi-
variable model in this study consisted of aortic pulse
wave velocity as the dependent variable and age, SBP,
waist circumference, fasting serum glucose, hs-CRP
and HIV infection as independent variables. This
showed that age (β = 0.065, p < 0.001), SBP (β = 0.017,
p = 0.043) and HIV infection (β = 0.53, p = 0.037) were
all independent predictors of aortic PWV in this study
group (overall R2 of the model = 0.33, p < 0.001). This
suggests that along with age and blood pressure, HIV
infection is independently associated with greater aor-
tic stiffness.
Determinants of regional aortic distensibility
In order to investigate the associations between re-
gional AD and other study parameters of the meta-
bolic syndrome and HIV infection, all 203 subjects
were included in this analysis. Associations betweenanthropometric, metabolic and HIV-related characteris-
tics and aortic AD are presented in Table 3. In agree-
ment with the published literature, aortic distensibility
was negatively correlated with age, systolic blood pres-
sure, diastolic blood pressure, visceral fat mass, fasting
serum glucose and hs-CRP levels at all levels measured.
Importantly, HIV infection was also associated with
Table 3 Associations between PWV and study characteristics of HIV and the metabolic syndrome
Aortic distensibility (mmHg-1)
Pulse wave velocity Ascending Proximal descending Abdominal
r p r p r p r p
Age (years) 0.52 <0.001 −0.41 <0.001 −0.37 <0.001 −0.29 <0.001
BMI (kg/m2) 0.20 0.043 −0.15 0.11 −0.23 <0.001 −0.22 <0.001
Visceral Fat (cm2) 0.24 0.008 −0.09 0.28 −0.25 <0.001 −0.22 0.01
Glucose (mmol/l) 0.15 0.049 −0.13 0.12 −0.24 <0.001 −0.17 0.03
Triglycerides (mmol/L) 0.13 0.09 −0.07 0.37 −0.20 0.01 −0.24 <0.001
HDL-C (mmol/L) −0.14 0.07 0.01 0.99 0.08 0.34 0.09 0.26
hsCRP (mg/L) 0.33 <0.001 −0.14 0.01 −0.30 <0.001 −0.26 <0.001
SBP (mmHg) −0.27 <0.001 −0.29 <0.001 −0.32 <0.001 −0.36 <0.001
DBP (mmHg) 0.20 <0.001 −0.17 <0.02 −0.21 <0.001 −0.23 <0.001
Waist circumference (cm) 0.19 0.02 −0.15 0.08 −0.21 <0.001 −0.31 <0.001
Cholesterol (mmol/L) 0.13 0.87 −0.12 0.14 −0.16 0.04 −0.11 0.18
HOMA-IR 0.09 0.39 −0.08 0.35 −0.15 0.06 −0.15 0.05
Past or present smoking 0.28 <0.001 −0.17 0.03 −0.18 0.03 −0.10 0.20
Viral load (copies/mL) 0.06 0.56 −0.12 0.30 −0.12 0.29 −0.04 0.69
Nadir CD4 count (106/L) −0.13 0.30 −0.06 0.62 0.09 0.42 0.16 0.17
Current CD4 count (106/L) 0.26 0.014 −0.14 0.23 −0.02 0.83 −0.05 0.67
PIs 0.06 0.51 0.11 0.23 0.03 0.75 −0.11 0.24
NRTIs 0.11 0.22 −0.10 0.27 −0.17 0.08 −0.22 0.02
NNRTIs 0.05 0.58 −0.18 0.06 −0.18 0.05 −0.12 0.18
Duration of HAART (years) 0.20 0.09 −0.12 0.36 −0.07 0.57 −0.10 0.42
HIV infection 0.23 0.001 −0.21 0.01 −0.25 <0.001 −0.21 0.01
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addition, as expected, BMI, waist circumference and trigly-
ceride levels were negatively correlated with proximal de-
scending and negatively with distal descending thoracic
aortic distensibility (Table 3). In a similar pattern to that
seen with PWV, there was no association between dur-
ation of HAART, antiretroviral class, viral load or nadir
CD4 count and aortic AD. To investigate if there were any
independent predictors of pulse wave velocity, multi-
variable regression was used as described above. The
strongest stepwise multivariable models in this study
consisted of aortic distensibility (Ao, PDA, DDA) as the
dependent variables and age, BMI, SBP, fasting serum
glucose, presence of the metabolic syndrome, smoking
status and HIV infection as independent variables.
This showed that age (Ao β = −0.108, PDA β = −0.05,
DDA β = −0.06, all p < 0.001), SBP (Ao β = −0.09, PDA
β = −0.03, DDA β = −0.04, all p < 0.01) and HIV infec-
tion (Ao β = −0.41, PDA β = −0.08, DDA β = −1.2, all
p <0.02) were all independent predictors of aortic AD
at all levels measured. In addition, again as expected
BMI was an independent predictor of DDA (β = − 0.12,
p = 0.001). Overall R2 of the models; Ao = 0.48, PDA 0.43,
DDA 0.39, all p < 0.001. This suggests that along with age,blood pressure and BMI, HIV infection is independently
associated with increased aortic stiffness.
Discussion
This study has shown that, after matching for potential
confounders, HIV infection is independently associated
with increased aortic PWV and decreased aortic disten-
sibility, both sensitive markers of reduced aortic elastic
function. In addition HIV infection is an independent
predictor of both increased pulse wave velocity and de-
creased aortic distensibility, clinical measures of aortic
stiffness linked to increased cardiovascular mortality.
The size of this detrimental effect is similar to that seen
with the metabolic syndrome, a powerful cardiovascular
risk factor. We have shown that HIV and the metabolic
syndrome are additive in their negative effects on PWV
and aortic distensibility, suggesting that both are risk
factors that act in different ways to impair vascular elas-
ticity. The mechanism of vascular alterations in patients
with HIV may be secondary to direct effects of the HIV
virus on vascular function, including direct alteration in
endothelial function, inflammation, and modification of
aortic wall vascular smooth muscle cell behaviour and
extra-cellular matrix composition.
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There is significant evidence that HIV infection is asso-
ciated with chronic systemic and vascular inflammation
even in patients on stable HAART with preserved CD4
counts and HIV RNA levels < 50 copies/ml, [8,26] and
these patients also have a greater burden of subclinical
atherosclerosis [7]. Elevations in inflammatory markers,
such as CRP, are associated with both increased arterial
stiffness [27] and a higher risk of mortality [28]. In sup-
port of a chronic inflammatory HIV-related vasculopathy
explaining our findings, a recent 18 F-FDG-PET study
demonstrated signs of increased arterial inflammation in
treated subjects with HIV [8]. Moreover, hsCRP was not
only elevated in patients with HIV in this study but was
also positively correlated to aortic PWV and negatively
correlated to AD at all three levels, and furthermore was
strongly correlated with visceral fat, which is thought to
play a central role in this inflammatory process, with
macrophage release of IL-6 and TNF-α [29] both which
are associated with increased PWV. This may suggest a
role for elevated visceral fat in vascular elastic dysfunc-
tion in treated HIV [30].
This study has demonstrated impaired vascular function
in HIV subjects, independent of traditional risk factors,
and, together with other studies of contemporary cohorts
of patients with treated HIV, suggest that chronic in-
flammation in HIV infection may partially underlie the
reduced vascular function and premature atheroscler-
osis. Prospective studies to reduce chronic inflamma-
tion beyond HAART are required to investigate whether
or not this improves vascular inflammation and function
and ultimately reduces atherosclerotic risk in patients
with HIV.
Endothelial dysfunction in HIV
Endothelial dysfunction is a common feature of athero-
sclerosis [31]. There is a growing body of evidence sug-
gesting HIV itself may have deleterious effects on
endothelial function. Patients with HIV (but without
the metabolic syndrome) have been shown to have re-
duced vascular reactivity in a pattern similar to that
seen in type 2 diabetes mellitus [32]. The direct effect of
HIV on endothelial biology has been extensively investi-
gated. As a result of increased secretion of monocyte
chemo-attractant protein 1 [33] and increased expres-
sion of the adhesion molecules, vascular cell adhesion
molecule-1 (VCAM-1) intercellular adhesion molecule
1 and E-selectin [6], vascular endothelium from patients
with HIV have increased monocyte adherence and mono-
cyte migration into the vascular intima during atheroscler-
otic plaque development [34]. In addition, several HIV
proteins, notably Tat and gp120 are themselves associated
with endothelial cell activation and increased expression
cell adhesion molecules [35]. Put together with theevidence that HIV infection affects lipid processing [5]
and is associated with lower HDL cholesterol, lower
apolipoprotein B levels (in advanced disease) [36] and
smaller LDL cholesterol particles, this environment
provides an atherogenic milieu [37]. Although studies
have now shown that HAART may to some extent reduce
endothelial activation, it does not appear to completely
ameliorate the effects of HIV infection, suggesting that
even during complete virological suppression, endothelial
dysfunction persists and continues to promote athero-
sclerosis (and excess cardiovascular risk) in HIV [38,39].The additive effect of treated HIV infection and the
metabolic syndrome on arterial stiffness
The detrimental effect of the metabolic syndrome on
aortic stiffness is well established [40-42]. This study has
not only shown that treated HIV infection has a similar
sized effect on aortic stiffness to the metabolic syndrome,
but has also shown that the combination of HIV and the
metabolic syndrome are additive in their negative effects.
This suggests that patients with both are likely to be at
even higher risk of cardiovascular events. As hs-CRP was
significantly higher in HIV subjects with the MS compared
to HIV subjects without the MS, and CRP has been shown
to be a marker of excess risk, [41] inflammation is a po-
tential unifying mechanism that may underlie the patho-
genesis of vascular disease in both groups.Study limitations
Due to the observational nature of this study, it is not
possible to confirm causality or mechanisms which
might underlie the increased aortic PWV and decreased
aortic distensibility in patients with HIV. The study was
not powered to detect differences in HAART-naïve and
treated subjects. Nor was it possible to determine the ef-
fects of individual anti-retroviral medications on vascular
function. Given the beneficial effect of antiretroviral treat-
ments on the vasculature and improved markers of vascu-
lar function that are observed after commencement of
antiretroviral therapy [38,43], antiretroviral agents are an
unlikely cause of the vascular dysfunction. Nevertheless,
longitudinal studies are needed to investigate this further.
However, by including both HAART naïve and HAART
treated patients this study provides a representative data-
set of HIV infected subjects in the UK.
Distensibility was calculated using pulse pressure mea-
surements taken from brachial blood pressure rather than
central blood pressure recordings. Although we accept
central pressure recording may have changed the absolute
aortic distensibility measures, given the magnitude of the
changes the DDA segment (i.e. up to 45% change in dis-
tensibility), the pattern of change, i.e. the main finding of
this paper would not be expected to be affected.
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Given the increase in cardiovascular events and cardiovas-
cular related mortality in HIV-infected patients treated
with effective antiretroviral therapy, identifying those at
higher cardiovascular risk is of great clinical importance.
We have shown that patients with treated HIV have re-
duced vascular function, which is independent of the
metabolic syndrome and other traditional cardiovascular
risk factors, suggesting a virus-related aetiology, such as
chronic inflammation. Importantly we have shown that
the magnitude of the effect of treated HIV infection is the
same as that of the metabolic syndrome, a well-established
and powerful predictor of cardiovascular mortality. Given
the additive effect of HIV and the metabolic syndrome on
reducing vascular function, aggressive management of
both HIV and the metabolic syndrome are likely needed
to reduce the high incidence of vascular disease in this
population.
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